Analysts think MBRX stock price could increase by 2373%
Mar 14, 2025, 11:25 AM
-32.04%
What does MBRX do
Moleculin Biotech, a Houston-based clinical-stage pharmaceutical company, focuses on developing treatments for tumors and viruses with three core technologies and six drug candidates. Established in 2016, it employs 18 people and has candidates showing human activity in trials.
3 analysts think MBRX stock price will increase by 2372.73%. The current median analyst target is $28.56 compared to a current stock price of $1.16. The lowest analysts target is $28.28 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.